brand logo

Am Fam Physician. 2008;78(4):434

The article “Diagnosis and Management of Diastolic Dysfunction and Heart Failure,” (March 1, 2006, page 841) contained two errors in the first paragraph of page 845. The words dihydropyridine and nondihydropyridine were misspelled. Also, there was an error in describing the indications and relative contraindications for use of these two classes of drugs (dihydropyridine and nondihydropyridine). The sentences should have read as follows: “However, nondihydropyridine calcium channel blockers (e.g., diltiazem [Cardizem]) and verapamil (Calan), should not be used in patients with bradycardia, conduction defects, or severe heart failure caused by left ventricular systolic dysfunction.30 Instead, nondihydropyridines, such as diltiazem and verapamil, should be used for rate control and angina when beta blockers are contraindicated or ineffective.” The article has been corrected online.

Continue Reading

More in AFP

Copyright © 2008 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.